CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
09-10-2019
NHS to receive £8m from Aspen over anti-competitive practices
15-08-2019
Piotr Swat / Shutterstock.com
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service (NHS), according to objections filed by the UK Competition and Markets Authority (CMA).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
CMA, competition, antitrust, NHS, prochlorperazine, Competition and Markets Authority, collusion, drug suppliers
